



Clinical trial results:

Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy and Pharmacodynamics of IMG-7289 in Patients with Essential Thrombocythemia

Summary

EudraCT number	2019-003659-13
Trial protocol	DE GB IT
Global end of trial date	23 March 2023

Results information

Result version number	v1 (current)
This version publication date	29 March 2024
First version publication date	29 March 2024

Trial information

Trial identification

Sponsor protocol code	MK-3453-003
-----------------------	-------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04254978
WHO universal trial number (UTN)	-
Other trial identifiers	Imago: IMG-7289-CTP-201

Notes:

Sponsors

Sponsor organisation name	Merck Sharp & Dohme LLC
Sponsor organisation address	126 East Lincoln Avenue, P.O. Box 2000, Rahway, NJ, United States, 07065
Public contact	Clinical Trials Disclosure, Merck Sharp & Dohme LLC, ClinicalTrialsDisclosure@merck.com
Scientific contact	Clinical Trials Disclosure, Merck Sharp & Dohme LLC, ClinicalTrialsDisclosure@merck.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	23 March 2023
Is this the analysis of the primary completion data?	Yes
Primary completion date	23 March 2023
Global end of trial reached?	Yes
Global end of trial date	23 March 2023
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

This is a Phase 2b open label study of an orally administered LSD1 inhibitor, Bomedemstat (MK-3543, formerly called IMG-7289), in patients with essential thrombocythemia.

This study investigates the following:

- The safety and tolerability of Bomedemstat
- The pharmacodynamic effect of Bomedemstat

Protection of trial subjects:

This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	08 September 2020
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 20
Country: Number of subjects enrolled	United States: 7
Country: Number of subjects enrolled	United Kingdom: 8
Country: Number of subjects enrolled	Italy: 14
Country: Number of subjects enrolled	Germany: 2
Country: Number of subjects enrolled	New Zealand: 6
Country: Number of subjects enrolled	Hong Kong: 16
Worldwide total number of subjects	73
EEA total number of subjects	16

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0

Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	34
From 65 to 84 years	37
85 years and over	2

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

94 participants were screened for the study. Of these, 21 participants were considered as screen failures and did not enter the treatment phase of the study.

Period 1

Period 1 title	Initial Treatment Period (ITP)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Arm title	Bomedemstat
-----------	-------------

Arm description:

Bomedemstat was administered daily for 169 consecutive days of the initial treatment period. After completing 169 days of treatment, qualifying participants continued into additional treatment periods of 169 days each, for as long as the participant continued to derive clinical benefit.

Arm type	Experimental
Investigational medicinal product name	Bomedemstat
Investigational medicinal product code	
Other name	MG-7289 MK-3543
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Bomedemstat administered daily for 169 consecutive days

Number of subjects in period 1	Bomedemstat
Started	73
Completed	64
Not completed	9
Consent withdrawn by subject	3
Adverse event, non-fatal	5
Lack of efficacy	1

Period 2

Period 2 title	Additional Treatment Period (ATP)
Is this the baseline period?	No
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Arm title	Bomedemstat
------------------	-------------

Arm description:

Bomedemstat was administered daily for 169 consecutive days of the initial treatment period. After completing 169 days of treatment, qualifying participants continued into additional treatment periods of 169 days each, for as long as the participant continued to derive clinical benefit.

Arm type	Experimental
Investigational medicinal product name	Bomedemstat
Investigational medicinal product code	
Other name	MG-7289 MK-3543
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Bomedemstat administered daily for 169 consecutive days

Number of subjects in period 2^[1]	Bomedemstat
Started	63
Completed	52
Not completed	11
Consent withdrawn by subject	3
Physician decision	1
Adverse event, non-fatal	7

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: One participant completed the initial treatment period (ITP) but did not continue into the additional treatment period (ATP)

Baseline characteristics

Reporting groups

Reporting group title	Bomedemstat
-----------------------	-------------

Reporting group description:

Bomedemstat was administered daily for 169 consecutive days of the initial treatment period. After completing 169 days of treatment, qualifying participants continued into additional treatment periods of 169 days each, for as long as the participant continued to derive clinical benefit.

Reporting group values	Bomedemstat	Total	
Number of subjects	73	73	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	34	34	
From 65-84 years	37	37	
85 years and over	2	2	
Age Continuous			
Units: Years			
arithmetic mean	64.8		
standard deviation	± 10.40	-	
Sex: Female, Male			
Units: Participants			
Female	42	42	
Male	31	31	
Race (Customized)			
Units: Subjects			
American Indian or Alaska Native	0	0	
Asian	18	18	
Native Hawaiian or Other Pacific Islander	0	0	
Black or African American	3	3	
White	51	51	
More than one race	0	0	
Unknown or Not Reported	0	0	
Aboriginal	1	1	
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	1	1	
Not Hispanic or Latino	71	71	
Unknown or Not Reported	1	1	

End points

End points reporting groups

Reporting group title	Bomedemstat
Reporting group description: Bomedemstat was administered daily for 169 consecutive days of the initial treatment period. After completing 169 days of treatment, qualifying participants continued into additional treatment periods of 169 days each, for as long as the participant continued to derive clinical benefit.	
Reporting group title	Bomedemstat
Reporting group description: Bomedemstat was administered daily for 169 consecutive days of the initial treatment period. After completing 169 days of treatment, qualifying participants continued into additional treatment periods of 169 days each, for as long as the participant continued to derive clinical benefit.	

Primary: Number of Participants Who Discontinue Study Treatment Due to an AE

End point title	Number of Participants Who Discontinue Study Treatment Due to an AE ^[1]
End point description: An AE is any undesirable physical, psychological or behavioral effect experienced by a patient during participation in the study, in conjunction with the use of the drug or biologic, whether or not product-related. This includes any untoward signs or symptoms experienced by the patient from the time of first dose with study treatment until completion of the study. The number of participants who discontinued study treatment due to an AE is reported.	
End point type	Primary
End point timeframe: Up to approximately 30 months	
Notes: [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No statistical analyses were planned for this endpoint.	

End point values	Bomedemstat			
Subject group type	Reporting group			
Number of subjects analysed	73			
Units: Participants	11			

Statistical analyses

No statistical analyses for this end point

Primary: Number of Participants Who Experienced an Adverse Event (AE)

End point title	Number of Participants Who Experienced an Adverse Event (AE) ^[2]
End point description: An AE is any undesirable physical, psychological or behavioral effect experienced by a participant during the study, in conjunction with the use of the drug or biologic, whether or not product related. This includes any untoward signs or symptoms experienced by the participant from the time of first dose with study treatment until completion of the study. The number of participants who experienced an AE is reported.	
End point type	Primary

End point timeframe:

Up to approximately 30 months

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were planned for this endpoint.

End point values	Bomedemstat			
Subject group type	Reporting group			
Number of subjects analysed	73			
Units: Participants	73			

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants with Platelet Count $\leq 400\text{k}/\mu\text{L}$

End point title	Percentage of Participants with Platelet Count $\leq 400\text{k}/\mu\text{L}$ ^[3]
-----------------	--

End point description:

Blood samples were collected at pre-specified timepoints to determine platelet counts. The percentage of participants who achieved reduction in platelet count to $\leq 400\text{k}/\mu\text{L}$ in the absence of new thrombolytic events is reported.

End point type	Primary
----------------	---------

End point timeframe:

Up to day 169

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No between-group statistical analyses were performed for this endpoint.

End point values	Bomedemstat			
Subject group type	Reporting group			
Number of subjects analysed	64			
Units: Percentage of Participants				
number (confidence interval 95%)	76.6 (64.3 to 86.2)			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Up to approximately 30 months

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	23.0
--------------------	------

Reporting groups

Reporting group title	Bomedemstat
-----------------------	-------------

Reporting group description:

Bomedemstat was administered daily for 169 consecutive days of the initial treatment period. After completing 169 days of treatment, qualifying patients continued into additional treatment periods of 169 days each, as long as the participant continued to derive clinical benefit.

Serious adverse events	Bomedemstat		
Total subjects affected by serious adverse events			
subjects affected / exposed	27 / 73 (36.99%)		
number of deaths (all causes)	2		
number of deaths resulting from adverse events	2		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute myeloid leukaemia			
subjects affected / exposed	1 / 73 (1.37%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 1		
Invasive ductal breast carcinoma			
subjects affected / exposed	1 / 73 (1.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Vasculitis			
subjects affected / exposed	1 / 73 (1.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Surgical and medical procedures			
Rotator cuff repair			

subjects affected / exposed	1 / 73 (1.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	1 / 73 (1.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Dyspnoea paroxysmal nocturnal			
subjects affected / exposed	1 / 73 (1.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Epistaxis			
subjects affected / exposed	1 / 73 (1.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pulmonary embolism			
subjects affected / exposed	1 / 73 (1.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory failure			
subjects affected / exposed	1 / 73 (1.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Femoral neck fracture			
subjects affected / exposed	1 / 73 (1.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Fall			

subjects affected / exposed	1 / 73 (1.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Contusion			
subjects affected / exposed	2 / 73 (2.74%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Post procedural haemorrhage			
subjects affected / exposed	1 / 73 (1.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Traumatic haematoma			
subjects affected / exposed	1 / 73 (1.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	1 / 73 (1.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac failure			
subjects affected / exposed	1 / 73 (1.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Transient ischaemic attack			
subjects affected / exposed	1 / 73 (1.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Thrombocytopenia			
subjects affected / exposed	4 / 73 (5.48%)		
occurrences causally related to treatment / all	3 / 4		
deaths causally related to treatment / all	0 / 0		

Anemia			
subjects affected / exposed	1 / 73 (1.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Chronic gastritis			
subjects affected / exposed	1 / 73 (1.37%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Abdominal pain			
subjects affected / exposed	1 / 73 (1.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Mouth haemorrhage			
subjects affected / exposed	1 / 73 (1.37%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Lower gastrointestinal haemorrhage			
subjects affected / exposed	1 / 73 (1.37%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Inguinal hernia			
subjects affected / exposed	1 / 73 (1.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal haemorrhage			
subjects affected / exposed	2 / 73 (2.74%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Ileal ulcer			
subjects affected / exposed	1 / 73 (1.37%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			

Panniculitis			
subjects affected / exposed	1 / 73 (1.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Arthritis			
subjects affected / exposed	1 / 73 (1.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Chondrocalcinosis			
subjects affected / exposed	1 / 73 (1.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Haematoma muscle			
subjects affected / exposed	1 / 73 (1.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal chest pain			
subjects affected / exposed	1 / 73 (1.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pain in extremity			
subjects affected / exposed	1 / 73 (1.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Synovitis			
subjects affected / exposed	1 / 73 (1.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Arthralgia			
subjects affected / exposed	2 / 73 (2.74%)		
occurrences causally related to treatment / all	2 / 3		
deaths causally related to treatment / all	0 / 0		

Infections and infestations Diverticulitis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 2 / 73 (2.74%) 0 / 2 0 / 0		
Gastroenteritis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 1 / 73 (1.37%) 0 / 1 0 / 0		
Pneumonia subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 3 / 73 (4.11%) 0 / 3 0 / 0		
COVID-19 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 1 / 73 (1.37%) 0 / 1 0 / 0		
Pneumonia aspiration subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 1 / 73 (1.37%) 0 / 1 0 / 1		
Skin infection subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 1 / 73 (1.37%) 0 / 1 0 / 0		
Metabolism and nutrition disorders Hypervolaemia subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 1 / 73 (1.37%) 0 / 1 0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Bomedemstat		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	72 / 73 (98.63%)		
Vascular disorders			
Hot flush			
subjects affected / exposed	4 / 73 (5.48%)		
occurrences (all)	6		
General disorders and administration site conditions			
Fatigue	Additional description: General disorders and administration site conditions		
subjects affected / exposed	21 / 73 (28.77%)		
occurrences (all)	35		
Influenza like illness	Additional description: General disorders and administration site conditions		
subjects affected / exposed	9 / 73 (12.33%)		
occurrences (all)	10		
Oedema peripheral	Additional description: General disorders and administration site conditions		
subjects affected / exposed	11 / 73 (15.07%)		
occurrences (all)	15		
Respiratory, thoracic and mediastinal disorders			
Oropharyngeal pain			
subjects affected / exposed	4 / 73 (5.48%)		
occurrences (all)	4		
Epistaxis			
subjects affected / exposed	7 / 73 (9.59%)		
occurrences (all)	8		
Psychiatric disorders			
Insomnia			
subjects affected / exposed	6 / 73 (8.22%)		
occurrences (all)	8		
Investigations			
Weight decreased			
subjects affected / exposed	7 / 73 (9.59%)		
occurrences (all)	8		
Blood creatinine increased			
subjects affected / exposed	4 / 73 (5.48%)		
occurrences (all)	8		
Injury, poisoning and procedural complications			

Procedural pain subjects affected / exposed occurrences (all)	4 / 73 (5.48%) 4		
Limb injury subjects affected / exposed occurrences (all)	4 / 73 (5.48%) 4		
Contusion subjects affected / exposed occurrences (all)	18 / 73 (24.66%) 25		
Nervous system disorders			
Dizziness subjects affected / exposed occurrences (all)	11 / 73 (15.07%) 12		
Headache subjects affected / exposed occurrences (all)	12 / 73 (16.44%) 26		
Paraesthesia subjects affected / exposed occurrences (all)	5 / 73 (6.85%) 10		
Syncope subjects affected / exposed occurrences (all)	4 / 73 (5.48%) 4		
Dysgeusia subjects affected / exposed occurrences (all)	43 / 73 (58.90%) 62		
Blood and lymphatic system disorders			
Anaemia subjects affected / exposed occurrences (all)	14 / 73 (19.18%) 35		
Neutropenia subjects affected / exposed occurrences (all)	8 / 73 (10.96%) 12		
Thrombocytopenia subjects affected / exposed occurrences (all)	23 / 73 (31.51%) 47		
Gastrointestinal disorders			

Gingival bleeding			
subjects affected / exposed	6 / 73 (8.22%)		
occurrences (all)	6		
Abdominal discomfort			
subjects affected / exposed	4 / 73 (5.48%)		
occurrences (all)	4		
Abdominal pain			
subjects affected / exposed	6 / 73 (8.22%)		
occurrences (all)	7		
Flatulence			
subjects affected / exposed	4 / 73 (5.48%)		
occurrences (all)	4		
Dyspepsia			
subjects affected / exposed	6 / 73 (8.22%)		
occurrences (all)	6		
Diarrhoea			
subjects affected / exposed	15 / 73 (20.55%)		
occurrences (all)	22		
Constipation			
subjects affected / exposed	29 / 73 (39.73%)		
occurrences (all)	35		
Vomiting			
subjects affected / exposed	5 / 73 (6.85%)		
occurrences (all)	5		
Nausea			
subjects affected / exposed	10 / 73 (13.70%)		
occurrences (all)	17		
Large intestine polyp			
subjects affected / exposed	4 / 73 (5.48%)		
occurrences (all)	4		
Haemorrhoids			
subjects affected / exposed	4 / 73 (5.48%)		
occurrences (all)	4		
Skin and subcutaneous tissue disorders			
Skin ulcer			

subjects affected / exposed	4 / 73 (5.48%)		
occurrences (all)	4		
Rash			
subjects affected / exposed	4 / 73 (5.48%)		
occurrences (all)	4		
Pruritus			
subjects affected / exposed	14 / 73 (19.18%)		
occurrences (all)	17		
Nail disorder			
subjects affected / exposed	4 / 73 (5.48%)		
occurrences (all)	4		
Hyperhidrosis			
subjects affected / exposed	4 / 73 (5.48%)		
occurrences (all)	4		
Ecchymosis			
subjects affected / exposed	4 / 73 (5.48%)		
occurrences (all)	5		
Dry skin			
subjects affected / exposed	4 / 73 (5.48%)		
occurrences (all)	5		
Alopecia			
subjects affected / exposed	14 / 73 (19.18%)		
occurrences (all)	17		
Musculoskeletal and connective tissue disorders			
Pain in extremity			
subjects affected / exposed	9 / 73 (12.33%)		
occurrences (all)	18		
Neck pain			
subjects affected / exposed	6 / 73 (8.22%)		
occurrences (all)	6		
Myalgia			
subjects affected / exposed	6 / 73 (8.22%)		
occurrences (all)	6		
Muscular weakness			

subjects affected / exposed	5 / 73 (6.85%)		
occurrences (all)	6		
Muscle spasms			
subjects affected / exposed	6 / 73 (8.22%)		
occurrences (all)	6		
Joint effusion			
subjects affected / exposed	4 / 73 (5.48%)		
occurrences (all)	4		
Bone pain			
subjects affected / exposed	5 / 73 (6.85%)		
occurrences (all)	9		
Back pain			
subjects affected / exposed	12 / 73 (16.44%)		
occurrences (all)	13		
Arthralgia			
subjects affected / exposed	29 / 73 (39.73%)		
occurrences (all)	75		
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	5 / 73 (6.85%)		
occurrences (all)	9		
Upper respiratory tract infection			
subjects affected / exposed	4 / 73 (5.48%)		
occurrences (all)	6		
Gastroenteritis			
subjects affected / exposed	5 / 73 (6.85%)		
occurrences (all)	5		
Cellulitis			
subjects affected / exposed	4 / 73 (5.48%)		
occurrences (all)	5		
COVID-19			
subjects affected / exposed	19 / 73 (26.03%)		
occurrences (all)	19		
Metabolism and nutrition disorders			
Decreased appetite			

subjects affected / exposed	6 / 73 (8.22%)		
occurrences (all)	8		
Iron deficiency			
subjects affected / exposed	7 / 73 (9.59%)		
occurrences (all)	7		
Gout			
subjects affected / exposed	4 / 73 (5.48%)		
occurrences (all)	5		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
17 March 2020	Amendment 1: The main purpose of the amendment was to update the inclusion and exclusion criteria and to modify the DLT criteria per FDA request.
19 October 2020	Amendment 2: The main purpose of the amendment was to increase the number of enrolled participants from 40 to 60. The amendment also updated the titration of the study treatment and clarified the adverse event reporting criteria.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported